GW is the global leader in developing cannabinoid-based medicines. From our experience in multiple sclerosis treatment, GW is now also developing products to treat rare and catastrophic forms of childhood-onset epilepsy.

GW’s vision is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs.
Justin Gover, Chief Executive Officer